Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
about
Neo-adjuvant chemotherapy for invasive bladder cancerMechanisms of Progranulin Action and Regulation in Genitourinary CancersRole of copper transporters in platinum resistanceRisk based neoadjuvant chemotherapy in muscle invasive bladder cancerMuscle-invasive urothelial bladder cancer: an update on systemic therapyOptimal management of muscle-invasive bladder cancer - a reviewBladder cancer in 2011: the dawn of personalized medicineRole of systemic chemotherapy in urothelial urinary bladder cancerMultimodal management of muscle-invasive bladder cancerPerioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial CarcinomaCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?Bladder Sparing Approaches for Muscle-Invasive Bladder CancersManagement of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgeryOutcome of urinary bladder cancer after combined therapiesBladder cancer in the elderly patient: challenges and solutionsRadical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial CarcinomaDownstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 diseasePooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancerPlatinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder CancerMolecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder CancerSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Systemic therapy for bladder cancer finally comes into a new age.A place for precision medicine in bladder cancer: targeting the FGFRs.Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.Bladder cancer: narrowing the gap between evidence and practiceRefining patient selection for neoadjuvant chemotherapy before radical cystectomyA 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment.Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy.Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors.Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.The role of EGFR family inhibitors in muscle invasive bladder cancer: a review of clinical data and molecular evidenceSignificance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial.Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data.A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy.Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
P2860
Q24247506-D841693D-CB24-4458-BF59-08648D2B4FEAQ26741917-27A9393A-39CD-44D9-B514-140F904849EAQ26767028-9C741966-7243-4D32-86B9-0F7A385816E2Q26773664-FA7FA2B4-3A45-46F8-B0B5-DAC4C9E79FA5Q26775780-1D7C4FC5-39ED-418B-A485-9275DBB4F089Q26784038-E811B44F-5C35-4257-BDFE-7212BA28F04DQ26998718-523C70DF-C831-486C-B6E6-E52890D1B04FQ27010323-CB7B37BD-C07A-4960-9C34-58DD1CD57C54Q27011624-D7E9B0C8-C1B5-4927-8A9A-1F9EAB2652F9Q27024948-772B2CFA-A73E-434C-B782-1F5E90E59BFBQ27026717-4411F851-44A3-4A58-BD76-F5574DC56ABEQ28066214-08C8F225-14CF-4424-8C89-062740D09674Q28072814-B4659EE7-39C3-4E80-BF36-CDD9A559A324Q28074930-E66D6EAD-122E-4CA4-A81D-810F4F08D3E1Q28076180-381B4863-32D6-4D6F-8F06-2929CF3B25E0Q28082782-139851BB-AD47-4757-B6F2-FCF41027395BQ28084159-06E6EE73-63EA-445B-B21F-8AFD21F76F03Q28084715-2A32BE6F-6307-452A-B55B-559BD8E19F44Q28262766-D7C5C600-50B9-478D-A681-2E9BDAF1C7F7Q28278664-96959251-0B5D-4AEE-8706-3205B81B72DFQ28552143-FEDA5325-8B36-4A36-AD16-E09F8A56CB63Q28552735-3EA62D79-1A7C-46CB-B255-628A83DCD005Q30240816-5DF7A621-A44B-428D-9179-2329DCA9EBC4Q30249047-B5C85BE9-9FE7-47CD-A258-7DB2095AB067Q30249143-B96BC619-97EF-4E81-AF27-688569046F84Q30277868-4801B127-168A-4C96-8279-F84550D5B8E9Q30362052-64D69EF8-0FA2-4F75-9EA7-03034CAA3229Q30408866-7C3443BF-7835-49AE-BFB2-E6BD0CBDF4F0Q30421675-346F457C-7529-4C29-A594-1E839D28479EQ30434237-8DEB10AA-A7DE-4F66-BAF2-61A8E3A5FC9DQ30437629-6834CF0E-1002-4E85-8A0E-E0BF943B37D3Q30459452-F6556196-CD47-4CC1-8E4E-F441395EF3B8Q30485127-8B216EB8-AD0B-4D03-954D-59DDF9D58943Q30538788-104F6553-A204-4E5B-AF85-7B5AAADCDB1DQ30563985-6EEEA39E-9CFF-4278-9B69-FB86B5C0DBFAQ30845020-9252F5F4-7F09-48CE-B738-6D633271E9ADQ30870825-9B5732FD-FBE0-4825-A28D-F41E7EB24C8CQ30976026-84984C38-B73B-471C-A2EB-3F4D6733B7C3Q30981992-97CE73B5-BC81-4984-A9C6-FAFFF3EB8992Q33360846-6BDDE1A1-2CD4-4D81-8FB6-62986FA1C555
P2860
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@ast
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@en
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@nl
type
label
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@ast
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@en
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@nl
prefLabel
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@ast
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@en
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@nl
P2093
P356
P1476
Neoadjuvant chemotherapy plus ...... cally advanced bladder cancer.
@en
P2093
Catherine M Tangen
David P Wood
Derek Raghavan
Donald L Trump
E David Crawford
H Barton Grossman
Michael F Sarosdy
Nicholas J Vogelzang
Ralph W deVere White
Ronald B Natale
P304
P356
10.1056/NEJMOA022148
P407
P577
2003-08-01T00:00:00Z